Cover Image
市場調查報告書

遲發性運動異常:開發平台分析

Tardive Dyskinesia - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 229806
出版日期 內容資訊 英文 56 Pages
訂單完成後即時交付
價格
Back to Top
遲發性運動異常:開發平台分析 Tardive Dyskinesia - Pipeline Review, H2 2015
出版日期: 2015年07月22日 內容資訊: 英文 56 Pages
簡介

遲發性運動異常是引起不自主運動的障礙。症狀有臉部歪曲、手指抽痛、下巴顫動、咀嚼式的蠕動、吐舌頭等不自主運動。一旦服用神經鬆弛劑會造成嚴重副作用。

本報告提供遲發性運動異常的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊,再加上最新的新聞和發表等資訊。

簡介

  • 調查範圍

遲發性運動異常 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的開發企業

  • Auspex Pharmaceuticals, Inc.
  • Contera Pharma ApS
  • Medicure Inc.
  • Neurocrine Biosciences, Inc.
  • Synchroneuron Inc.

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • acamprosate calcium SR
  • Drugs for Tardive Dyskinesia
  • dutetrabenazine ER
  • Tardoxal
  • valbenazine

最近的開發平台趨勢

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC6918IDB

Summary

Global Markets Direct's, 'Tardive Dyskinesia - Pipeline Review, H2 2015', provides an overview of the Tardive Dyskinesia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Tardive Dyskinesia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tardive Dyskinesia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Tardive Dyskinesia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Tardive Dyskinesia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Tardive Dyskinesia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Tardive Dyskinesia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Tardive Dyskinesia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Tardive Dyskinesia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Tardive Dyskinesia Overview
  • Therapeutics Development
    • Pipeline Products for Tardive Dyskinesia - Overview
    • Pipeline Products for Tardive Dyskinesia - Comparative Analysis
  • Tardive Dyskinesia - Therapeutics under Development by Companies
  • Tardive Dyskinesia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Tardive Dyskinesia - Products under Development by Companies
  • Tardive Dyskinesia - Companies Involved in Therapeutics Development
    • Addex Therapeutics Ltd
    • Contera Pharma ApS
    • Neurocrine Biosciences, Inc.
    • Synchroneuron Inc.
    • Teva Pharmaceutical Industries Limited
  • Tardive Dyskinesia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
  • Assessment by Molecule Type
    • Drug Profiles
    • acamprosate calcium SR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dipraglurant IR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs for Tardive Dyskinesia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dutetrabenazine ER - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • valbenazine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Tardive Dyskinesia - Recent Pipeline Updates
  • Tardive Dyskinesia - Dormant Projects
  • Tardive Dyskinesia - Product Development Milestones
    • Featured News & Press Releases
      • Jun 16, 2015: Teva Advances Pipeline of Movement Disorder Assets with Announcement of Positive Top-Line Data from the First Pivotal Study of Investigational Treatment for Patients with Tardive Dyskinesia
      • Feb 03, 2015: Auspex Pharmaceuticals Completes Enrollment in a Pivotal Clinical Trial of SD-809 in Tardive Dyskinesia
      • Oct 30, 2014: Auspex Pharmaceuticals Initiates Second Pivotal Clinical Trial for SD-809 in Tardive Dyskinesia
      • Oct 30, 2014: Neurocrine Biosciences Receives Breakthrough Therapy Designation for NBI-98854 in Tardive Dyskinesia
      • Oct 20, 2014: Neurocrine Announces Initiation Of Phase III Study For VMAT2 Inhibitor NBI-98854
      • Jul 17, 2014: Auspex Pharmaceuticals Initiates Pivotal Phase 2/3 Clinical Trial for SD-809 in Tardive Dyskinesia
      • Feb 24, 2014: Synchroneuron Announces First Patient Dosed in Phase 2 Tardive Dyskinesia Clinical Trial
      • Jan 09, 2014: Neurocrine Announces 12-Week Safety Results From Initial Phase IIB Study Of VMAT2 Inhibitor NBI-98854
      • Jan 06, 2014: Neurocrine Announces Positive Results of VMAT2 Inhibitor NBI-98854 in Kinect 2 Study
      • Sep 09, 2013: Neurocrine Announces Phase IIb Results Of VMAT2 Inhibitor NBI-98854 For Treatment Of Tardive Dyskinesia
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Tardive Dyskinesia, H2 2015
  • Number of Products under Development for Tardive Dyskinesia - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Tardive Dyskinesia - Pipeline by Addex Therapeutics Ltd, H2 2015
  • Tardive Dyskinesia - Pipeline by Contera Pharma ApS, H2 2015
  • Tardive Dyskinesia - Pipeline by Neurocrine Biosciences, Inc., H2 2015
  • Tardive Dyskinesia - Pipeline by Synchroneuron Inc., H2 2015
  • Tardive Dyskinesia - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Tardive Dyskinesia Therapeutics - Recent Pipeline Updates, H2 2015
  • Tardive Dyskinesia - Dormant Projects, H2 2015

List of Figures

  • Number of Products under Development for Tardive Dyskinesia, H2 2015
  • Number of Products under Development for Tardive Dyskinesia - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top